Hikma sees 2020 sales growth after profit beats view on newer drugs

(Reuters) - Hikma Pharmaceuticals on Thursday forecast sales growth this year after it surpassed analysts' expectations for annual operating profit and revenue in 2019, boosted by higher demand for its injectable treatments and newly launched drugs.The company expects revenue from its injectables division to grow in the low to mid-single digits and its generics unit to be between $700 million and $750 million (542 million-580 million pounds). Sales for its branded segment is expected to grow by..